GPC Biotech has announced plans to restructure, a process that will include layoffs of approximately 44% of the company’s current active workforce. Both the German and U.S. workforce will be cut. The company is “retaining key personnel needed to achieve the Company’s medium- and longer-term goals,” according to a GPC statement. Bernd R. Seizinger, M.D., Ph.D., chief executive officer, said, “Our goal of having approximately two years of operating cash on hand at the end of 2...